查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1492256

CD40 配體市場：按類型、應用程式和最終用戶分類 - 2024-2030 年全球預測

CD40 Ligand Market by Type (Monoclonal Antibody, Polyclonal Antibody), Application (Autoimmune Disease Treatment, Immunotherapy, Vaccine Development), End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

CD40配體市場規模預計2023年為6.9721億美元，預計2024年將達到7.345億美元，2030年將達到10.1229億美元，複合年成長率為5.47%。

CD40配體（CD40L）是主要存在於T細胞上的重要分子，在免疫反應中扮演重要角色。因此，它們在免疫疾病、某些癌症和自體免疫疾病的治療方法的開發中發揮著重要作用。在治療應用中，基於 CD40L 的療法對於治療淋巴瘤和白血病等疾病至關重要，並且可能透過增強免疫系統對抗癌細胞的能力而擴展到固體癌。此外，CD40L在自體免疫疾病中的功能表明，其調節可能會降低全身性紅斑性狼瘡和類風濕性關節炎等疾病的嚴重程度。在疫苗開發中，CD40L介導的免疫反應增強有可能顯著提高疫苗針對多種疾病的效力。 CD40配體市場的成長受到以下因素的推動：技術進步擴大了CD40L標靶療法的功效和範圍、相關疾病盛行率的上升、公共和私人投資支持的持續研究和開發以及新的研究和開發受到多種因素的影響，包括有利的因素促進治療方法的核准和市場進入的監管條件。市場擴張的機會包括將 CD40L 療法與個人基因譜相匹配的個人化醫療、加強合作以加速開發，以及進入醫療投資迅速增加的新興市場。然而，市場面臨複雜且成本高昂的監管核准流程以及高昂的製造成本等挑戰，阻礙了准入。此外，CD40L 在各種疾病中的作用背後的複雜科學進一步增加了普遍有效治療方法的開發的複雜性。這是未來研究的一個令人興奮的領域，因為對先進藥物傳輸系統、聯合治療和基因療法等創新方法的投資將改善治療結果並減少副作用。

主要市場統計
基準年[2023] 6.9721 億美元
預測年份 [2024] 7.345 億美元
預測年份 [2030] 1,012,290,000 美元
複合年成長率（%） 5.47%

區域洞察

美洲，特別是美國和加拿大，對慢性發炎和癌症治療有著濃厚的興趣。該地區的特點是強大的研究活動、大量的專利申請以及積極的法規環境，這些都刺激了對先進醫療保健解決方案的需求。同樣，歐洲卓越的生物技術和製藥基礎設施，特別是在德國、法國和英國，以歐洲藥品管理局 (EMA) 簡化的核准流程為基礎，並因其在自體免疫疾病和癌症治療中的作用而得到認可。在亞太地區，中國、日本和印度正積極加強其醫療保健系統。中國正在擴大其生物製藥領域，日本在醫療保健技術方面不斷創新，印度正在探索具有成本效益的生物相似藥治療。所有這些努力都表明人們對 CD40 配體治療的興趣日益濃厚。同時，在中東和非洲（EMEA），沙烏地阿拉伯和阿拉伯聯合大公國等富裕國家正在投資尖端醫療保健研究，而非洲國家則專注於基本醫療保健需求，這表現出了多樣化的做法，包括逐步進行。這些地區的消費者需求和購買行為差異很大。在美洲和歐洲，消費者的意識很高，對強調藥物功效和安全性的下一代治療方法抱有很高的期望。亞太地區的消費者越來越注重健康，尋求先進的治療方法，但也注重成本。另一方面，在非洲，中東的富人對更先進的治療方法有著濃厚的興趣，但減輕醫療費用負擔仍然是首要關注的問題。

FPNV定位矩陣

FPNV定位矩陣對於評估CD40配體市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估，並檢查了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對 CD40 配體市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該行業競爭力的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對 CD40 配體市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 自體免疫疾病和癌症的發生率上升
      • 生物技術和分子生物學的進展
      • 醫療保健支出和研發投資增加
    • 抑制因素
      • 監管要求嚴格，產品開發高成本
    • 機會
      • 增加對免疫腫瘤學的投資
      • 生物技術和製藥巨頭之間合作的機會，以加速創新治療方法的開發和分銷
    • 任務
      • CD40配體的複雜機制
  • 市場區隔分析
    • 類型：針對多種應用的基於 CD40 配體的多株抗體的廣泛研究
    • 應用：CD40配體在免疫學和腫瘤學領域醫學進展的應用
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 CD40 配體市場：依類型

  • 單株抗體
  • 多株抗體

第7章 CD40 配體市場：依應用分類

  • 自體免疫疾病的治療
  • 免疫療法
  • 疫苗開發

第 8 章 CD40 配體市場：依最終用戶分類

  • 醫療服務提供方
  • 製藥公司
  • 調查機構

第9章美洲CD40配體市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區CD40配體市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲CD40配體市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • Kiniksa Pharmaceuticals 推動乾燥症新階段的免疫調節療法和類風濕性關節炎的最新研究成果
    • 異種移植的突破：Eledon Pharmaceuticals 的 tegopulvert 對於歷史性的豬對人類心臟移植至關重要
    • 賽諾菲將多發性硬化症治療藥物 Flexaliumab 推進第 3 期試驗
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-5D693B46BCF8

[192 Pages Report] The CD40 Ligand Market size was estimated at USD 697.21 million in 2023 and expected to reach USD 734.50 million in 2024, at a CAGR 5.47% to reach USD 1,012.29 million by 2030.

The CD40 Ligand (CD40L) is a critical molecule found predominantly on T cells, playing a vital role in immune responses. This makes it intensely relevant in developing treatments for immune disorders, specific cancers, and autoimmune diseases. In therapeutic applications, CD40L-based treatments are crucial for managing conditions such as lymphoma and leukemia, potentially extending to some solid tumors by boosting the immune system's ability to fight cancer cells. Furthermore, CD40L's function in autoimmune disorders suggests its modulation could lessen disease severity in ailments such as systemic lupus erythematosus and rheumatoid arthritis. In vaccine development, enhancing immune responses through CD40L could significantly improve vaccine efficacy against various diseases. CD40 Ligand market growth is influenced by several factors including technological advancements that increase the efficacy and scope of CD40L-targeted therapies, the rising prevalence of related diseases, ongoing research and development supported by public and private investments, and favorable regulatory conditions which expedite the approval and market entry of novel treatments. Opportunities for market expansion include personalizing medicine to tailor CD40L therapies to individual genetic profiles, fostering collaborations that speed development, and penetrating emerging markets where healthcare investments are escalating. However, the market faces challenges such as complex and costly regulatory approval processes and high production costs which hinder accessibility. Moreover, the intricate science behind CD40L's role across various diseases adds another layer of complexity to developing universally effective therapies. Investment in innovative approaches such as advanced drug delivery systems, combination therapies, and gene therapy enhance treatment outcomes and reduce side effects, making these promising areas for future research.

KEY MARKET STATISTICS
Base Year [2023] USD 697.21 million
Estimated Year [2024] USD 734.50 million
Forecast Year [2030] USD 1,012.29 million
CAGR (%) 5.47%

Regional Insights

In the Americas, particularly the United States and Canada, there is a strong focus on chronic inflammation and cancer therapies. The region is characterized by intense research activities, numerous patent filings, and a vigorous regulatory environment that fuels the demand for advanced healthcare solutions. Similarly, Europe's notable biotech and pharmaceutical infrastructure, especially in Germany, France, and the UK, fosters significant advancements in autoimmune and cancer treatments, supported by streamlined approval processes by the European Medical Agency (EMA). In the Asia Pacific, China, Japan, and India are aggressively pursuing enhancements in their healthcare systems. China is expanding its biopharmaceutical sector, Japan continues to innovate in healthcare technology, and India is pushing forward with research in cost-effective biosimilar treatments. All these efforts point to a growing interest in therapies that involve CD40 ligand. Meanwhile, the Middle East and Africa (EMEA) display a diverse approach; wealthier nations including Saudi Arabia and the UAE invest in cutting-edge healthcare research, whereas African countries focus more on foundational healthcare needs while gradually stepping into complex cancer treatment research. Consumer needs and purchasing behavior vary significantly across these regions. In the Americas and Europe, there is a high consumer awareness and an expectation for next-generation treatments, with a strong emphasis on drug efficacy and safety. Asia Pacific consumers are increasingly health-conscious, seeking advanced treatments but are sensitive to cost. In contrast, the primary concern in much of Africa remains essential healthcare affordability, though there is a keen interest in more sophisticated treatments among wealthier segments in the Middle East.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the CD40 Ligand Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising prevalence of autoimmune diseases and cancers
      • Advancements in biotechnology and molecular biology
      • Increased healthcare spending and R&D investments
    • Market Restraints
      • Stringent regulatory requirements and high cost of product development
    • Market Opportunities
      • Growing Investment in Immuno-Oncology
      • Opportunities for partnerships between biotech firms and pharmaceutical giants to accelerate innovative therapies development and distribution
    • Market Challenges
      • Complex mechanisms of the CD40 ligand
  • Market Segmentation Analysis
    • Type: Extensive research in CD40 Ligand based polyclonal antibodies for diverse applications
    • Application: Applications of CD40 Ligand in advancing medical treatments in field of immunology and oncology
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the CD40 Ligand Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the CD40 Ligand Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Kiniksa Pharmaceuticals Advances Immune-Modulating Therapies with a New Phase in Sjogren's Disease and Updated Rheumatoid Arthritis Study Results

Kiniksa Pharmaceuticals, Ltd., a player in developing treatments for autoimmune and cardiovascular diseases, has announced the beginning of a Phase 2b trial of their drug, abiprubart, in patients with Sjogren's Disease. In addition, the company revealed findings from the fourth cohort of a Phase 2 clinical trial for the same drug in treating rheumatoid arthritis. Abiprubart, which is still under investigation, is a humanized antibody aimed at disrupting the interaction between CD40 and CD40 ligand (CD154), a mechanism believed to regulate immune responses involved in these conditions. [Published On: 2024-04-02]

Breakthrough in Xenotransplantation: Eledon Pharmaceuticals' Tegoprubart Integral to Historic Pig-to-Human Heart Transplant

Eledon Pharmaceuticals, Inc. reported that its experimental treatment, tegoprubart, the company's investigational anti-CD40 antibody, played a key role in the immunosuppressive therapy used during a pioneering pig-to-human heart transplant. The procedure, the second of its kind, was conducted on September 20th at the University of Maryland Medical Center and involved a 58-year-old male patient with heart failure. The utilization of tegoprubart, an anti-CD40 antibody, marks a significant advancement in transplant medicine and genetic engineering. [Published On: 2023-09-24]

Sanofi Advances Promising Multiple Sclerosis Treatment, Frexalimab, into Phase 3 Trials

Sanofi is set to progress its novel drug candidate, frexalimab, into phase 3 trials following successful mid-stage results for the treatment of multiple sclerosis. In clinical studies, the higher dosage of frexalimab led to a significant 89% decline in the formation of gadolinium-enhancing T1 brain lesions, which are indicative of active disease inflammation, after 12 weeks. Furthermore, at the 24-week mark, a remarkable 96% of patients receiving this dose exhibited no new T1 lesions, highlighting the potential effectiveness of frexalimab in controlling disease progression. [Published On: 2023-06-01]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the CD40 Ligand Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the CD40 Ligand Market, highlighting leading vendors and their innovative profiles. These include Abcam Limited by Danaher Corporation, ACROBiosystems, Bio-Techne Corporation, BioLegend, Inc. by PerkinElmer, Inc., BPS Bioscience, Inc., Cell Signaling Technology, Inc., Creative Biolabs, Cytek Biosciences, Inc., Eledon Pharmaceuticals, Inc., Enzo Life Sciences, Inc.,, FUJIFILM Irvine Scientific., Gemini BioProducts LLC, Kiniksa Pharmaceuticals, Ltd., Leinco Technologies, Inc., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Sino Biological, Inc., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the CD40 Ligand Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Monoclonal Antibody
    • Polyclonal Antibody
  • Application
    • Autoimmune Disease Treatment
    • Immunotherapy
    • Vaccine Development
  • End-Users
    • Healthcare Providers
    • Pharmaceutical Companies
    • Research Institutions
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of autoimmune diseases and cancers
      • 5.1.1.2. Advancements in biotechnology and molecular biology
      • 5.1.1.3. Increased healthcare spending and R&D investments
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory requirements and high cost of product development
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing Investment in Immuno-Oncology
      • 5.1.3.2. Opportunities for partnerships between biotech firms and pharmaceutical giants to accelerate innovative therapies development and distribution
    • 5.1.4. Challenges
      • 5.1.4.1. Complex mechanisms of the CD40 ligand
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Extensive research in CD40 Ligand based polyclonal antibodies for diverse applications
    • 5.2.2. Application: Applications of CD40 Ligand in advancing medical treatments in field of immunology and oncology
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. CD40 Ligand Market, by Type

  • 6.1. Introduction
  • 6.2. Monoclonal Antibody
  • 6.3. Polyclonal Antibody

7. CD40 Ligand Market, by Application

  • 7.1. Introduction
  • 7.2. Autoimmune Disease Treatment
  • 7.3. Immunotherapy
  • 7.4. Vaccine Development

8. CD40 Ligand Market, by End-Users

  • 8.1. Introduction
  • 8.2. Healthcare Providers
  • 8.3. Pharmaceutical Companies
  • 8.4. Research Institutions

9. Americas CD40 Ligand Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific CD40 Ligand Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa CD40 Ligand Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Kiniksa Pharmaceuticals Advances Immune-Modulating Therapies with a New Phase in Sjogren's Disease and Updated Rheumatoid Arthritis Study Results
    • 12.3.2. Breakthrough in Xenotransplantation: Eledon Pharmaceuticals' Tegoprubart Integral to Historic Pig-to-Human Heart Transplant
    • 12.3.3. Sanofi Advances Promising Multiple Sclerosis Treatment, Frexalimab, into Phase 3 Trials
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CD40 LIGAND MARKET RESEARCH PROCESS
  • FIGURE 2. CD40 LIGAND MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CD40 LIGAND MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CD40 LIGAND MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CD40 LIGAND MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CD40 LIGAND MARKET DYNAMICS
  • FIGURE 7. GLOBAL CD40 LIGAND MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CD40 LIGAND MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CD40 LIGAND MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CD40 LIGAND MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS CD40 LIGAND MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS CD40 LIGAND MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES CD40 LIGAND MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES CD40 LIGAND MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. CD40 LIGAND MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. CD40 LIGAND MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CD40 LIGAND MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CD40 LIGAND MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CD40 LIGAND MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CD40 LIGAND MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CD40 LIGAND MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CD40 LIGAND MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CD40 LIGAND MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CD40 LIGAND MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CD40 LIGAND MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CD40 LIGAND MARKET SIZE, BY AUTOIMMUNE DISEASE TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CD40 LIGAND MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CD40 LIGAND MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CD40 LIGAND MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CD40 LIGAND MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CD40 LIGAND MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CD40 LIGAND MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CD40 LIGAND MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CD40 LIGAND MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CD40 LIGAND MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS CD40 LIGAND MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES CD40 LIGAND MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES CD40 LIGAND MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC CD40 LIGAND MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CD40 LIGAND MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM CD40 LIGAND MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM CD40 LIGAND MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM CD40 LIGAND MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM CD40 LIGAND MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM CD40 LIGAND MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM CD40 LIGAND MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 283. CD40 LIGAND MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. CD40 LIGAND MARKET, FPNV POSITIONING MATRIX, 2023